InterCure (NASDAQ:INCR) Trading Up 9.4% – Still a Buy?

InterCure Ltd. (NASDAQ:INCR) traded up 9.4% on Monday . The company traded as high as $0.9556 and last traded at $0.9560. 73,559 shares changed hands during trading, an increase of 24% from the average session volume of 59,395 shares. The stock had previously closed at $0.8740.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of InterCure in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

InterCure Trading Up 9.4%

The business’s 50-day moving average price is $0.87 and its two-hundred day moving average price is $0.94. The company has a market capitalization of $52.27 million, a P/E ratio of 31.87 and a beta of 1.38. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.48 and a quick ratio of 0.97.

InterCure (NASDAQ:INCR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.10) earnings per share for the quarter. The firm had revenue of $23.15 million for the quarter.

InterCure Company Profile

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.